Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Mabwell
Deal Size : $571.0 million
Deal Type : Licensing Agreement
Alphabet's Calico Weaves Anti-Aging Deal with China's Mabwell
Details : Mabwell will grant Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 for age-related diseases, in all regions except Greater China.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $25.0 million
June 27, 2025
Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Mabwell
Deal Size : $571.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ABBV-CLS-628
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 30, 2025
Lead Product(s) : ABBV-CLS-628
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-616
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : ABBV-CLS-616
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calico Announces Fosigotifator Selected for FDA Pilot Program for White Matter Disease
Details : ABBV-CLS-7262 (fosigotifator) is an eIF2B activator, a factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2024
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 14-C ABBV-CLS-7262
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : 14-C ABBV-CLS-7262
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-7262
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2024
Lead Product(s) : ABBV-CLS-7262
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access to ABBV-CLS-484
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-7262
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2023
Lead Product(s) : ABBV-CLS-7262
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-CLS-7262 is an eIF2B activator which targets eIF2B, a guanine nucleotide exchange factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-484,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : ABBV-CLS-484,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable